Health
Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with the blood cancer myeloma (also called multiple myeloma). Called Quest Flow Cytometry MRD for Myeloma, the new test provides comparable sensitivity as next-generation sequencing methods in detecting residual myeloma*, but at a fraction of the cost, supporting bet
About this update from Quest Diagnostics Incorporated
[{"type":"text","content":"New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing","length":123,"tagName":"p","attribs":{}},{"type":"text","content":"SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with the blood cancer myeloma (also called multiple myeloma). Called Quest Flow Cytometry MRD for Myeloma, the new test provides comparable sensitivity as next-generation sequencing methods in detecting residual myeloma*, but at a fraction of the cost, supporting better care and outcomes.","length":572,"tagName":"p"},{"type":"image","alt":"Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)","displaySize":"","headline":null,"caption":"Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":190,"url":"https://media.zenfs.com/en/prnewswire.com/328ba769d21514205fa2226e0dacf99b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/10t_J0fsHk4Z61kiPTCtrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMzNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/328ba769d21514205fa2226e0dacf99b","width":400,"height":190}},"href":"https://mma.prnewswire.com/media/200883/quest_diagnostics_incorporated_logo_logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Our Flow Cytometry MRD for Myeloma test harnesses cutting-edge science and technology to deliver ultrasensitive insights from a noninvasive blood test, thereby improving care and value for patients and the healthcare system," said board-certified oncologist and hematologist Yuri Fesko, M.D., Senior Vice President and Chief Medical Officer, Quest Diagnostics. "This new test merges this elite performance with improved access, given Quest's approximately 7,000 phlebotomy sites across the United States, helping to illuminate a path to better health for more patients."","length":595,"tagName":"p"},{"type":"text","content":"Advancing disease detection for a prevalent blood cancer","length":56,"tagName":"p"},{"type":"text","content":"Myeloma is a cancer of ...